To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cas No.: | |
| Chemical Name: | VCP979 |
| Cat. No. | Product name | Field of application |
| DC74349 | NuP-3 | NuP-3 is a potent, selective MAPK13 and MAPK14 inhibitor with IC50 of 7 and 14 nM, respectively. |
| DC74347 | NC-p38i NC-37 | Non-canonical p38α inhibitor NC-37 (NC-p38i NC-37) is a potent, highly selective, non-canonical inhibitor of p38α, inhibits TAB1-induced p38α autophosphorylation in vitro with IC50 of 0.27 uM. |
| DC48953 | Emprumapimod | Emprumapimod is a potent, orally bioavailable and selective inhibitor of p38α MAPK directly inhibits LPS-induced IL-6 production from RPMI-8226 cell (IC50=100 pM). Emprumapimod can be used for the research of dilated cardiomyopathy and acute inflammatory pain. |
| DC4173 | VX-745 | VX-745 is a potent and selective inhibitor of p38α MAPK and p38β MAPK with IC50 of 10 nM and 220 nM, respectively. |
| DC1061 | VX-702 (VX702) | VX-702 is a highly selective inhibitor of p38 MAPKα with IC50 of 4-20 nM. |
| DC8255 | SD-06 | SD-06 is a p38 MAP kinase inhibitor; inhibits p38α with an IC50 value of 170 nM and inhibits LPS-stimulated TNF-release in rats (83% inhibition at 1mg/kg, po). |
| DC11829 | MW-150 | MW-150 is a novel potent, selective, CNS penetrant and orally active inhibitor of p38α MAPK with Ki of 101 nM |
| DC7711 | Losmapimod | Losmapimod (GW856553X) is a selective, potent, and orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively. Phase 3. |
| DC10417 | Acumapimod (BCT197) | Acumapimod (BCT197) is an orally active p38 MAP kinase inhibitor, with an IC50 of less than 1 μM for p38α. |
| DC79776 | WEIZ-WX-04-008 | WEIZ-WX-04-008 (Compound 1) is a covalent Lysine-targeting MKK7 inhibitor with IC50 of 738 nM. |